Studies have found that the use of BI2536 which is an ATP-binding domain inhibitor of Polo-like kinase-1 (PLK1), in combination with Cisplatin on esophageal cancer cells can enhance the activity of caspase-3, cause pyroptosis, and in parallel to enhance DNA damage55. The gene discussed is PLK1; the disease is esophageal cancer.